CA2101189A1 - Agglomerated hydrophilic complexes with multi-phasic release characteristics - Google Patents

Agglomerated hydrophilic complexes with multi-phasic release characteristics

Info

Publication number
CA2101189A1
CA2101189A1 CA2101189A CA2101189A CA2101189A1 CA 2101189 A1 CA2101189 A1 CA 2101189A1 CA 2101189 A CA2101189 A CA 2101189A CA 2101189 A CA2101189 A CA 2101189A CA 2101189 A1 CA2101189 A1 CA 2101189A1
Authority
CA
Canada
Prior art keywords
release characteristics
phasic release
agglomerated
hydrophilic complexes
phasic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2101189A
Other languages
French (fr)
Other versions
CA2101189C (en
Inventor
Anand R. Baichwal
John N. Staniforth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penwest Pharmaceuticals Co
Original Assignee
Mendell Edward Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mendell Edward Co Inc filed Critical Mendell Edward Co Inc
Publication of CA2101189A1 publication Critical patent/CA2101189A1/en
Application granted granted Critical
Publication of CA2101189C publication Critical patent/CA2101189C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Abstract

The present invention relates to a controlled release formulation which includes a therapeutically active medicament, a heterodisperse gum matrix, a pharmaceutically acceptable diluent, and an effective amount of a pharmaceutically acceptable surfactant and/or wetting agent to provide a multi-phasic controlled release of a therapeutically active medicament. The invention also relates to a method of preparing the same.
CA002101189A 1992-07-30 1993-07-23 Agglomerated hydrophilic complexes with multi-phasic release characteristics Expired - Lifetime CA2101189C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/922,312 1992-07-30
US07/922,312 US5472711A (en) 1992-07-30 1992-07-30 Agglomerated hydrophilic complexes with multi-phasic release characteristics

Publications (2)

Publication Number Publication Date
CA2101189A1 true CA2101189A1 (en) 1994-01-31
CA2101189C CA2101189C (en) 1999-09-21

Family

ID=25446878

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002101189A Expired - Lifetime CA2101189C (en) 1992-07-30 1993-07-23 Agglomerated hydrophilic complexes with multi-phasic release characteristics

Country Status (13)

Country Link
US (3) US5472711A (en)
EP (2) EP0581676B1 (en)
JP (1) JP3967389B2 (en)
KR (1) KR100342299B1 (en)
AT (1) ATE311861T1 (en)
AU (1) AU669531B2 (en)
CA (1) CA2101189C (en)
DE (1) DE69333927T2 (en)
ES (1) ES2252731T3 (en)
FI (1) FI117962B (en)
HU (1) HUT67622A (en)
IL (1) IL106253A (en)
MX (1) MX9304485A (en)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6716454B2 (en) 1994-09-23 2004-04-06 Laboratorie Innothera, Société Anonyme Therapeutic combination of vitamin and calcium in unitary galenic tablet form, a method of obtaining it, and the use thereof
US6471994B1 (en) * 1995-01-09 2002-10-29 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US6936277B2 (en) * 1995-01-09 2005-08-30 J. Rettenmaier & Soehne Gmbh & Co. Kg Pharmaceutical excipient having improved compressibility
US6540993B1 (en) * 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
ES2322405T3 (en) 1996-07-08 2009-06-19 Penwest Pharmaceuticals Co. CONTROLLED LIBERATION MATRIX FOR INSOLUBLE DRUGS IN HIGH DOSE.
IN186245B (en) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6337091B1 (en) 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
ATE424810T1 (en) 1998-12-11 2009-03-15 Nostrum Pharmaceuticals Inc A DELAYED-RELEASE TABLET CONTAINING A HYDROCOLLOID AND A CELLULOSE ETHER
US6159491A (en) * 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
EP1183014B1 (en) 1999-06-14 2003-10-08 Cosmo S.p.A. Controlled release and taste masking oral pharmaceutical compositions
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
AU2003246326B2 (en) * 1999-09-30 2006-07-27 Penwest Pharmaceuticals Co. Sustained Release Matrix Systems for Highly Soluble Drugs
IL143375A0 (en) * 1999-09-30 2002-04-21 Penwest Pharmaceuticals Co Sustained release matrix systems for highly soluble drugs
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
MXPA02009534A (en) 2000-03-30 2003-05-14 Squibb Bristol Myers Co Sustained release beadlets containing stavudine.
US6337083B1 (en) * 2000-04-05 2002-01-08 International Fluidics Oral delivery method and composition for solid medications or dietary supplements
US6358526B1 (en) * 2000-08-16 2002-03-19 Rexall Sundown Method of making tablets and tablet compositions produced therefrom
US6749845B2 (en) * 2001-02-15 2004-06-15 Aeropharm Technology, Inc. Modulated release particles for lung delivery
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
HUP0501071A3 (en) 2001-03-13 2007-06-28 Penwest Pharmaceutical Co Chronotherapeutic dosage forms
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US20030113366A1 (en) * 2001-12-14 2003-06-19 Macgregor Alexander Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
MXPA04009701A (en) * 2002-04-05 2005-05-27 Penwest Pharmaceuticals Co Sustained release metoprolol formulations.
AU2003231156A1 (en) * 2002-04-30 2003-11-17 Npd Llc Multi-phasic delivery via transmucosal absorption of appetite suppressants and craving reduction medicaments
KR100409435B1 (en) * 2002-05-07 2003-12-18 한국전자통신연구원 Method of manufacturing an active layer and a method for manufacturing a MOS transistor using the same
AU2003261298A1 (en) * 2002-08-02 2004-02-23 Penwest Pharmaceuticals Company Sustained release formulations of metformin
US7445796B2 (en) * 2002-08-19 2008-11-04 L. Perrigo Company Pharmaceutically active particles of a monomodal particle size distribution and method
EP3241550B1 (en) * 2002-11-22 2020-07-22 Grünenthal GmbH (1r, 2r)-3-(dimenthyl amino-1-ethyl-2-methyl-propyl) phenol for treating painful inflammations
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
MXPA06003100A (en) 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Delayed released dosage forms.
MXPA06003101A (en) * 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms.
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US20060004076A1 (en) * 2004-06-30 2006-01-05 Inflabloc Pharmaceuticals, Inc. Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US20060228413A1 (en) * 2005-02-28 2006-10-12 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
CN101212958A (en) * 2005-06-29 2008-07-02 万能药生物有限公司 Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
EP1743638A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Pharmaceutical formulations of substituted pyrazoline compounds
WO2007009683A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr.Esteve, S.A. Pharmaceutical formulations of substituted pyrazoline compounds
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2648280C (en) 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US8187659B2 (en) * 2006-05-02 2012-05-29 Jerry Robertson Real Estate Llc Solid medicament dosage form consumption aid
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
DK2735338T3 (en) 2008-09-05 2019-04-23 Gruenenthal Gmbh PHARMACEUTICAL COMBINATION OF 3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) -PHENOL AND PREGABALINE OR GABAPENTIN
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
WO2011023392A1 (en) 2009-08-28 2011-03-03 Grünenthal GmbH Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an antiepileptic
SI2582366T1 (en) 2010-06-15 2016-02-29 Gruenenthal Gmbh Pharmaceutical combination for the treatment of pain
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
TW201343201A (en) * 2012-03-06 2013-11-01 Otsuka Pharma Co Ltd Sustained release oral solid preparation
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9308196B2 (en) 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US8912226B2 (en) 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US9345689B2 (en) 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
CA2902911C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10166185B2 (en) 2015-06-09 2019-01-01 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
WO2017192921A1 (en) 2016-05-05 2017-11-09 Monosol Rx, Llc Enhanced delivery epinephrine compositions
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2993836A (en) * 1958-02-20 1961-07-25 Dow Chemical Co Sustained release tablets
US3079303A (en) * 1958-12-11 1963-02-26 Smith Kline French Lab Basic tablet granulation and process of using same
NL265428A (en) * 1960-06-06
US3133863A (en) * 1961-03-10 1964-05-19 Strong Cobb Arner Inc Sustained release therapeutic tablet compositions comprising organic solvent-gelled gums
US3147187A (en) * 1962-09-10 1964-09-01 Don Hall Lab Sustained release pharmaceutical
US3388041A (en) * 1964-01-27 1968-06-11 Richardson Merrell Inc High dosage sustained release tablet
GB1097207A (en) * 1964-08-24 1967-12-29 Collett & Co As Process for the preparation of sustained action tablets
US3456049A (en) * 1965-05-25 1969-07-15 Ciba Geigy Corp Gradual-release tablet
US3726690A (en) * 1965-10-22 1973-04-10 Kelco Co Acidified food products containing xanthomonas colloid
US3864469A (en) * 1967-12-16 1975-02-04 Hoechst Ag Xanthines in pharmaceutical preparations and for stabilization of vitamins
US3627583A (en) * 1969-04-29 1971-12-14 Sucrest Corp Direct compression vehicles
US3639169A (en) * 1969-04-29 1972-02-01 Sucrest Corp Direct compression vehicles and method therefor
US3629393A (en) * 1969-09-11 1971-12-21 Nikken Chemicals Co Ltd Release-sustaining-tablet
GB1359643A (en) * 1970-09-28 1974-07-10 Controlled Medications Controlled release medicament
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
US3773920A (en) * 1971-07-14 1973-11-20 Nikken Chemicals Co Ltd Sustained release medicinal composition
US3836618A (en) * 1971-12-23 1974-09-17 American Home Prod Process for the uniform distribution of a drug on a granulated base
FR2183546B1 (en) * 1972-05-10 1975-06-20 Servier Lab
US3963832A (en) * 1973-01-24 1976-06-15 Teijin Limited Liquid or pasty dentifrice and process for its preparation
US4013820A (en) * 1974-11-07 1977-03-22 Abbott Laboratories Universally useable tableting ingredients
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
HU179474B (en) * 1978-02-24 1982-10-28 Laszlo Gyarmati Process for preparing solid oral pharmaceutical compositons with increased length of activity and with a regulated release of the active material
US4361545A (en) * 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4308251A (en) * 1980-01-11 1981-12-29 Boots Pharmaceuticals, Inc. Controlled release formulations of orally-active medicaments
US4439453A (en) * 1980-12-22 1984-03-27 Monsanto Company Directly compressible acetaminophen granulation
DE3127237A1 (en) * 1981-07-10 1983-01-20 Hoechst Ag, 6000 Frankfurt STOMACHICABLE MEDICINAL FORMS OF XANTHINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
US4525345A (en) * 1981-12-24 1985-06-25 Verex Laboratories, Inc. Constant order release, solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4556678A (en) * 1982-06-24 1985-12-03 Key Pharmaceuticals, Inc. Sustained release propranolol tablet
US4698264A (en) * 1982-08-02 1987-10-06 Durkee Industrial Foods, Corp. Particulate composition and process for making same
US4698101A (en) * 1982-08-30 1987-10-06 Suomen Sokeri Oy (Finnish Sugar Company Ltd.) Binder-diluent composition and method
DE3435325A1 (en) * 1983-04-09 1986-04-17 Nikken Chemicals Co., Ltd., Tokio/Tokyo LONG-TERM THEOPHYLLIN TABLET AND METHOD FOR THE PRODUCTION THEREOF
US4717713A (en) * 1983-10-31 1988-01-05 Research Corporation Controlled release liquid pharmaceutical
JPS60219238A (en) * 1984-04-14 1985-11-01 Hayashibara Biochem Lab Inc Formed product containing slowly disintegrating pullulan and its production
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
JPS6124516A (en) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd Long active tablet
GB8426152D0 (en) * 1984-10-16 1984-11-21 Reckitt & Colmann Prod Ltd Medicinal compositions
DE3440288A1 (en) * 1984-11-05 1986-05-07 Gergely, Gerhard, Dr.-Ing., Wien PHARMACEUTICAL PREPARATION WITH A CONTENT OF AT LEAST ONE Mucous-irritating SUBSTANCE OR THE LIKE, PARTICULARLY PROFESSIONALS, AND METHOD FOR THE PRODUCTION THEREOF
US4695463A (en) * 1985-05-24 1987-09-22 Warner-Lambert Company Delivery system for active ingredients and preparation thereof
WO1987000044A1 (en) * 1985-07-02 1987-01-15 The Upjohn Company Therapeutic formulations with bimodal release characteristics
GB8518927D0 (en) * 1985-07-26 1985-09-04 Vincent Processes Ltd Tablets
GB8522453D0 (en) * 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
IT1191674B (en) * 1986-03-07 1988-03-23 Eurand Spa FORMULATIONS FOR THE PREPARATION OF PROLONGED-RELEASE DRUGS SUITABLE FOR ORAL ADMINISTRATION
US4855143A (en) * 1986-04-04 1989-08-08 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
GB8608818D0 (en) * 1986-04-11 1986-05-14 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
SE8601624D0 (en) * 1986-04-11 1986-04-11 Haessle Ab NEW PHARMACEUTICAL PREPARATIONS
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
JPH0826346B2 (en) * 1986-07-10 1996-03-13 株式会社林原生物化学研究所 Manufacturing method of solid oil-soluble substance
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics

Also Published As

Publication number Publication date
EP0581676A3 (en) 1995-06-07
DE69333927T2 (en) 2006-06-29
EP1582205A2 (en) 2005-10-05
US5478574A (en) 1995-12-26
KR100342299B1 (en) 2002-11-18
DE69333927D1 (en) 2006-01-12
EP0581676B1 (en) 2005-12-07
IL106253A0 (en) 1993-11-15
HUT67622A (en) 1995-04-28
EP1582205A3 (en) 2008-07-30
FI117962B (en) 2007-05-15
AU4185593A (en) 1994-02-03
EP0581676A2 (en) 1994-02-02
JPH06172221A (en) 1994-06-21
ES2252731T3 (en) 2006-05-16
US5670168A (en) 1997-09-23
MX9304485A (en) 1994-04-29
AU669531B2 (en) 1996-06-13
FI933393A0 (en) 1993-07-29
CA2101189C (en) 1999-09-21
FI933393A (en) 1994-01-31
HU9302104D0 (en) 1993-10-28
JP3967389B2 (en) 2007-08-29
US5472711A (en) 1995-12-05
KR940005291A (en) 1994-03-21
IL106253A (en) 1998-03-10
ATE311861T1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
CA2101189A1 (en) Agglomerated hydrophilic complexes with multi-phasic release characteristics
CA2004598A1 (en) Medicinal aerosol formulations
CA2337745A1 (en) Human growth hormone aqueous formulation
CA2123160A1 (en) Controlled release formulation
WO1997012583A3 (en) Stable compositions containing n-propargyl-1-aminoindan
CA2143107A1 (en) Enantiomerically pure .beta.-d-dioxolane-nucleosides
CA2203033A1 (en) Compounds and compositions for delivering active agents
CA2172616A1 (en) Tropyl 7-azaindol-3-ylcarboxyamides as antitussive agent
IE790756L (en) Cerebral therapeutic agent
CA2105887A1 (en) Bioerodible device for administering active ingredients
CA2104474A1 (en) Compositions and methods for topical administration of pharmaceutically active agents
CA2014889A1 (en) Intra-rectal pharmaceutical foam compositions
CA2142126A1 (en) Inhalation powder containing antistatic agent
CA2000763A1 (en) Dispersable formulation
CA2093282A1 (en) Intraoral medicament-releasing device
AU8188691A (en) The use of inositoltrisphosphate for the preparing of medicaments
CA2063273A1 (en) Surfactant compositions and methods
AU1691988A (en) Physiologically active agent for agricultural use
CA2042934A1 (en) Treatment of ocular hypertension with an ocular synergistic combination
ES2078175A1 (en) Pharmaceutical formulation containing clobetasone and tobramycin and applications thereof.
CA2192822A1 (en) Use of immunosuppressive agents for the treatment of schizophrenia
CA2185794A1 (en) Agent for relieving side effects caused by immunosuppressants
CA2042936A1 (en) Treatment of ocular hypertension with a synergistic combination for ophthalmic use
CA2182812A1 (en) Pharmaceutical composition for systemic transdermal administration containing the active agent morphine-6-glucuronide
CA2139781A1 (en) Ophthalmic topical composition containing (s)-timolol hemihydrate

Legal Events

Date Code Title Description
EEER Examination request